BioSpace News Archive

Creatv MicroTech, a privately-held biotechnology company has pioneered a blood test for the universal screening of early stage cancer. They will present their initial clinical data showing the ability to identify invasive cancer with 87% accuracy.

Persistence Market Research (PMR) delivers key insights on the global cell free protein expression market in its upcoming report titled, “Cell Free Protein Expression Market: Global Industry Analysis and Forecast, 2016–2024”.

In a new report titled “Hemoglobinopathy Market: Global Industry Analysis and Forecast, 2016–2024”, Persistence Market Research analyzes the performance of the global hemoglobinopathy market over an eight-year period and provides insights on the key factors and trends likely to influence the market during the forecast period (2016 – 2024).

ECG monitoring devices are experiencing a paradigm technological shift from resting ECG systems to portable Holter monitoring systems. According to a new report by Persistence Market Research (PMR), titled, “Holter Monitoring Systems Market: Global Industry Analysis and Forecast, 2016-2024”, this is attributed to advantages such as patient mobility, low prices, and longer period of patient monitoring.

Cellworks Multi-omics Biosimulation Delivers GBM and LGG Survival Predictors Above and Beyond Physician Prescribed Treatments

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented data from the first clinical studies evaluating the oral investigational agents TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, and TP-3654, a PIM kinase inhibitor, in p

-- No complement mediated toxicities and up to 70% clinical benefit¹ across multiple solid tumors -- Combination of AGEN1181 with Agenus’s balstilimab (PD-1) advancing in the clinic -- B. Riley to host conference call with Drs. Steven O’Day and Charles Drake on Next-Generation CTLA-4 agents - June 2, 2020 [29-May-2020] LEXINGTON, Mass. , May 29, 202

Endo International plc (the “Company”) (NASDAQ: ENDP) announced today the early tender results of the previously announced Exchange Offers and Consent Solicitations (each as defined below) by wholly owned subsidiaries Pa

- More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years(1) - Study conclusions are drawn from the largest dataset and longest follow-up to date of patients with BRAF-mutated melanoma treated with targeted therapy following the surgical removal of their cancer(1,2) - Data are from the five-year follow-up of the COMBI-AD trial presented at the ASCO20 Virtual Scientific Program(1)

First publication of primary analysis shows robust and durable clinical response in patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations; data also presented during ASCO 2020